CARspen Therapeutics

CARsgen Therapeutics is a China-based, Hong Kong-listed biopharmaceutical company focused on developing chimeric antigen receptor T-cell therapies for hematologic malignancies, solid tumors, and, more recently, autoimmune diseases. The company has built an integrated cell-therapy platform spanning target discovery, preclinical research, clinical development, and commercial-scale manufacturing. Its lead commercial product is zevorcabtagene autoleucel (Zevor-cel, CT053), a BCMA-directed autologous CAR-T approved in China for relapsed or refractory multiple myeloma. CARsgen is also advancing satricabtagene autoleucel (Satri-cel, CT041), a Claudin18.2-directed CAR-T for gastric and pancreatic cancers, along with next-generation autologous and allogeneic CAR-T programs such as CT071 and CT0596. The company positions itself as a platform-driven cell therapy developer with global rights to its pipeline and in-house technologies intended to improve efficacy, safety, and manufacturing efficiency.